SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Bezlotoxumab Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Innishannon
   County Cork - Ireland
   Telephone : 353 214329300
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.3 Other hazards
   None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
</table>

SECTION 4: First aid measures

4.1 Description of first aid measures

<table>
<thead>
<tr>
<th>Protection of first-aiders</th>
<th>No special precautions are necessary for first aid responders.</th>
</tr>
</thead>
<tbody>
<tr>
<td>If inhaled</td>
<td>If inhaled, remove to fresh air. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td>In case of skin contact</td>
<td>Wash with water and soap as a precaution. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td>In case of eye contact</td>
<td>Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.</td>
</tr>
<tr>
<td>If swallowed</td>
<td>If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.</td>
</tr>
</tbody>
</table>

4.2 Most important symptoms and effects, both acute and delayed
None known.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

<table>
<thead>
<tr>
<th>Suitable extinguishing media</th>
<th>Water spray</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alcohol-resistant foam</td>
</tr>
<tr>
<td></td>
<td>Carbon dioxide (CO2)</td>
</tr>
<tr>
<td></td>
<td>Dry chemical</td>
</tr>
</tbody>
</table>

| Unsuitable extinguishing media | None known. |

5.2 Special hazards arising from the substance or mixture

| Specific hazards during firefighting | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products      | Carbon oxides |

5.3 Advice for firefighters

| Special protective equipment       | Wear self-contained breathing apparatus for firefighting if nec- |
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

Version 1.9 Revision Date: 23.03.2020 SDS Number: 818320-00010 Date of last issue: 13.09.2019 Date of first issue: 22.07.2016

for firefighters

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:
Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s):
No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezlotoxumab</td>
<td>1246264-45-8</td>
<td>TWA</td>
<td>2 mg/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material: Chemical-resistant gloves

Skin and body protection:
Work uniform or laboratory coat.
Bezlotoxumab Formulation

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: Aqueous solution
Colour: Colorless to pale yellow
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, kinematic: No data available

Explosive properties: Not explosive
Bezlotoxumab Formulation

Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids): No data available
Molecular weight: No data available
Particle size: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Bezlotoxumab:
Acute toxicity (other routes of administration):
LD50 (Mouse): > 125 mg/kg
Application Route: Intravenous
Remarks: No adverse effect has been observed in acute toxicity tests.
Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:
Species : Mouse
NOAEL : 50 mg/kg
Application Route : Intravenous
Exposure time : 15 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 125 mg/kg
Application Route : Intravenous
Exposure time : 21 d
Remarks : No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Bezlotoxumab:
Inhalation : Symptoms: Nausea, Headache, Diarrhoea, Fever
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

Version 1.9  Revision Date: 23.03.2020  SDS Number: 818320-00010  Date of last issue: 13.09.2019

Date of first issue: 22.07.2016

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.
SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - In-
Bezlotoxumab Formulation

Further information


The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN